Name | Title | Contact Details |
---|
Pleasantview Industries Inc is a Santa Clarita, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Technology and Patent Research International is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Athos is a venture-backed startup developing a revolutionary product for the fitness and athletic market. We are creating next generation wearable technology that gives you real insight into how your body works as you move and combining it with a beautiful user experience that will fit right into your existing routine. Our goal is to empower you to make more informed decisions while pursuing a healthy, active lifestyle.
The Arc of Anchorage is a Anchorage, AK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.